Table 2 Alternative/novel treatments for FSGS
From: Focal segmental glomerulosclerosis: molecular genetics and targeted therapies
Circulating factors |
• Plasmapheresis/Immunoabsorption [57] |
• Galactose [106] |
Immune modulation |
• Rituximab |
Anti-fibrotic therapy |
• Tumor necrosis factor (TNF): Adalimumab, a human anti-TNF monoclonal antibody |
• Connective tissue growth factor (CTGF) [110]: FG-3019, a human monoclonal antibody against CTGF |
• Transforming growth factor β (TGF-β) [110]: Fresolimumab, a human monoclonal antibody directed against human TGF-β1, 2 and 3 |